Drug–drug interactions and tolerance in combining antituberculosis and antiretroviral therapy
- 7 September 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 4 (5) , 821-836
- https://doi.org/10.1517/14740338.4.5.821
Abstract
Worldwide, tuberculosis (TB) is one of the most important infectious diseases in subjects with HIV infection. Although effective therapy is available for both conditions, there are major problems in the concurrent treatment of HIV and TB co-infection. In this article the knowledge available on drug–drug interactions between anti-HIV and anti-TB compounds is analysed, particularly with regard to pharmacological interactions secondary to interference with cytochrome P450 enzymes. Within the same setting, facts and possible interpretations of the problems encountered in terms of tolerance and safety of the concurrent treatment of TB and HIV are also reviewed. Current guidelines, as well as additional possible strategies to be adopted in this particular co-morbidity setting are discussed.Keywords
This publication has 58 references indexed in Scilit:
- Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of EnfuvirtideClinical Pharmacokinetics, 2005
- Hepatotoxicity of AntiretroviralsDrug Safety, 2005
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Drug Interactions Between Antiretroviral Drugs and Comedicated AgentsClinical Pharmacokinetics, 2003
- Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with TuberculosisClinical Pharmacokinetics, 2002
- Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase InhibitorsClinical Pharmacokinetics, 2001
- Ritonavir Enables Combined Therapy with Rifampin and SaquinavirClinical Infectious Diseases, 1999
- DidanosineDrugs, 1996
- A prospective study of the risk of tuberculosis among HIV-infected patientsAIDS, 1993
- Clinical Pharmacokinetics of the Antituberculosis DrugsClinical Pharmacokinetics, 1984